Phone: 888-558-5227

651-644-8424 Email: getinfo@lktlabs.com

Fax: 888-558-7329

Web: lktlabs.com

## **Product Information**

Product ID P004080 CAS No. 315183-21-2

Chemical Name N'-[(6-oxo-5-prop-2-enyl-1-cyclohexa-2,4-dienylidene)methyl]-2-[4-

(phenylmethyl)-1-piperazinyl]acetohydrazide

**Synonym** (4-Benzylpiperazino)acetic acid (3-allyl-2-hyroxybenzylidene)hydrazide, 1-

Piperazineacetic acid, 2-(phenylmethyl)-,[[2-hydroxy-3-(2-propenyl)phenyl]

methylene]hyrrazide

 $\begin{array}{ll} \textbf{Formula} & C_{23}H_{28}N_4O_2 \end{array}$ Formula Wt. 392.50 **Melting Point** 

Purity ≥98%

Solubility 100mM in DMSO

Bulk quanitites available upon request

**Product ID** Size P004080 5 mg P004080 25 mg P004080 100 mg

Store Temp 4°C Ship Temp Ambient

**Description** PAC-1 (Procaspase Activating Compound 1) has been identified through high-throughput screening as a compound that may enhance the enzymatic activity of procaspase-3 in vitro. Procaspase-3 may be useful as an anticancer strategy due to its low frequency of mutations in cancer and expression of its enzyme in several types of cancers. PAC-1 converts procaspase-3 to active caspase-3 in vitro by chelating zinc ions and thereby inducing cell death in the tumor cells. In multiple cancer cell lines, PAC-1 was shown to trigger endoplasmic reticulum stress signaling and induce autophagy and mitochondria-mediated apotosis.

References Sarkar A, Balakrishnan K, Chen J, et al. Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget. 2016 Jan 19;7(3):3461-3476. PMID: 26658105.

> Roth HS, Hergenrother PJ. Derivatives of procaspase-activating compound 1 (PAC-1) and their anticancer activities. Curr Med Chem. 2016;23(3):201-241. PMID: 26630918.

> Seervi M, Sobhan PK, Joseph J, et al. ERO1alpha-dependent endoplasmic reticulum-mitochondrial calcium flux contributes to ER stress and mitochondrial permeabilization by procaspase-activating compound-1 (PAC-1). Cell Death Dis. 2013 Dec 19;4: e968, PMID: 24357799.

Lucas PW, Schmit JM, Peterson QP, et al. Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs. Invest New Drugs. 2011 Oct;29(5):901-911. PMID: 20499133.

Peterson QP, Goode DR, West DC, et al. PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. J Mol Biol. 2009 Apr 24;388(1):144-158. PMID: 19281821.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.